Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H11N2O2.Na |
Molecular Weight | 250.2284 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1
InChI
InChIKey=NCNYJCOBUTXCBR-IPZCTEOASA-M
InChI=1S/C13H12N2O2.Na/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;/h1-8,10H,9H2,(H,16,17);/q;+1/p-1/b6-5+;
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P24557|||Q8IUN1|||Q9HD82 Gene ID: 6916.0 Gene Symbol: TBXAS1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/14720071 |
11.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | DOMENAN Approved UseUnknown |
|||
Primary | XANBON Approved UseCerebral vasospasm and ischaemia following surgical management of subarachnoid haemorrhage. |
PubMed
Title | Date | PubMed |
---|---|---|
Thromboxane A2 and development of genetic hypertension in the Lyon rat strain. | 1990 Dec |
|
Heparin-protamine complexes cause pulmonary hypertension in goats. | 1995 Oct |
|
Effect of sodium ozagrel on the activity of rat CYP2D6. | 2007 Nov 14 |
|
Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome). | 2008 Mar |
Sample Use Guides
1 tablet (200 mg of the active ingredient) at a time, twice a day after breakfast and before bedtime (for asthma). Intravenous infusion of 80mg, twice a day, solute in 500ml normal saline or 5% glucose solution (cerebral vasospasm).
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C034364
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
DTXSID50172327
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
SUB03604MIG
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
DBSALT002123
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
23663942
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
100000085516
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
4X5577N3ET
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL11662
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
189224-26-8
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | |||
|
m8349
Created by
admin on Sat Dec 16 04:19:41 GMT 2023 , Edited by admin on Sat Dec 16 04:19:41 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD